Denali Therapeutics Inc (NASDAQ:DNLI) price on Thursday, July 03, fall -1.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $14.69.
A look at the stock’s price movement, the close in the last trading session was $14.9, moving within a range at $14.67 and $15.0. The beta value (5-Year monthly) was 1.328. Turning to its 52-week performance, $33.33 and $10.57 were the 52-week high and 52-week low respectively. Overall, DNLI moved 5.46% over the past month.
Denali Therapeutics Inc’s market cap currently stands at around $2.13 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-06.
Turning to the stock’s technical picture we see that short term indicators suggest on average that DNLI is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend DNLI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
DNLI’s current price about 1.77% and 1.31% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.49, while 7-day volatility ratio is 5.21% and 5.00% in the 30-day chart. Further, Denali Therapeutics Inc (DNLI) has a beta value of 1.36. Analysts have given the company’s stock an average 52-week price target of $32, forecast between a low of $32 and high of $32. Looking at the price targets, the low is -117.84% off current price level while to achieve the yearly target high, price needs to move -117.84%. Nonetheless, investors will most likely welcome a -117.84% jump to $32 which is the analysts’ median price.
If we refocus on Denali Therapeutics Inc (NASDAQ:DNLI), historical trading data shows that trading volumes averaged 1.72 over the past 10 days and 1.54 million over the past 3 months. The company’s latest data on shares outstanding shows there are 145.25 million shares.
The 13.46% of Denali Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 92.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.95 million on 2025-06-13, giving us a short ratio of 7.92. The data shows that as of 2025-06-13 short interest in Denali Therapeutics Inc (DNLI) stood at 921.0000000000001 of shares outstanding, with shares short falling to 12.1 million registered in 2025-05-15. Current price change has pushed the stock -33.26% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DNLI stock continues to rise going into the next quarter.
